Business Description
Proteome Sciences PLC
ISIN : GB0003104196
Total Employee Number:
32Description
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.05 | |||||
Equity-to-Asset | -1.16 | |||||
Debt-to-Equity | -1.66 | |||||
Debt-to-EBITDA | -9.06 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -16.02 | |||||
Beneish M-Score | -7.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -21.7 | |||||
3-Year Book Growth Rate | -120.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.07 | |||||
9-Day RSI | 47.91 | |||||
14-Day RSI | 48.96 | |||||
3-1 Month Momentum % | 20 | |||||
6-1 Month Momentum % | -55.56 | |||||
12-1 Month Momentum % | -76.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.13 | |||||
Quick Ratio | 0.09 | |||||
Cash Ratio | 0.05 | |||||
Days Inventory | 55.81 | |||||
Days Sales Outstanding | 46.61 | |||||
Days Payable | 99.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -28.51 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -2.16 | |||||
Operating Margin % | -70.98 | |||||
Net Margin % | -81.5 | |||||
EBITDA Margin % | -46.33 | |||||
FCF Margin % | -4.48 | |||||
OCF Margin % | -1.88 | |||||
ROA % | -35.72 | |||||
ROIC % | -10.93 | |||||
3-Year ROIIC % | -100.77 | |||||
ROC (Joel Greenblatt) % | -111.72 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.79 | |||||
EV-to-EBIT | -7.89 | |||||
EV-to-EBITDA | -12.1 | |||||
EV-to-Revenue | 5.6 | |||||
EV-to-FCF | -141.85 | |||||
Price-to-GF-Value | 0.7 | |||||
Price-to-Median-PS-Value | 0.7 | |||||
Earnings Yield (Greenblatt) % | -12.66 | |||||
FCF Yield % | -2.4 |
Proteome Sciences PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Proteome Sciences PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-25 | In 90 days | ||
| General meeting for 2025 | 2026-05-14 11:00 | 0.01 (+0.00%) | ||
| Annual report for 2025 | 2026-04-20 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-15 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-25 | 0.03 (+0.00%) | ||
| General meeting for 2024 | 2025-05-16 12:00 | 0.03 (+0.00%) | ||
| Annual report for 2024 | 2025-04-17 | 0.03 (+0.00%) | ||
| Fourth quarter earnings conference call for 2024 | 2025-04-11 10:30 | 0.02 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-10 | 0.03 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-09-13 | 0.04 (+0.00%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Proteome Sciences PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers